PMID- 34221306
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231107
IS  - 2040-6223 (Print)
IS  - 2040-6231 (Electronic)
IS  - 2040-6223 (Linking)
VI  - 12
DP  - 2021
TI  - Prevalence, prescriptions, outcomes and costs of type 2 diabetes patients with or 
      without prior coronary artery disease or stroke: a longitudinal 5-year 
      claims-data analysis of over 7 million inhabitants.
PG  - 20406223211026390
LID - 10.1177/20406223211026390 [doi]
LID - 20406223211026390
AB  - AIMS: To analyze the prevalence, comorbidities, outcomes and costs of type 2 
      diabetes mellitus (T2DM) patients with and without coronary artery disease (CAD) 
      or stroke in a population of over 7 million inhabitants. METHODS: T2DM patients 
      were identified in 2015 (accrual period) from the Ricerca e Salute (ReS) database 
      linking administrative records to demographics. Based on 2013-2015 information, 
      four cohorts were considered: #1 with CAD and/or stroke; #2 without CAD and/or 
      stroke; #3 with chronic CAD but no myocardial infarction or stroke; #4 with 
      chronic CAD undergoing percutaneous coronary interventions (PCI). 
      Hospitalizations, drugs and other outpatient care were assessed from 2015 to 
      2017. RESULTS: The prevalence of T2DM was 6% (441,085/7,365,954). CAD and/or 
      stroke in the previous 3 years affected 7.5% of T2DM patients (33,153); this 
      cohort was generally older, of male sex, with more comorbidities, prescriptions, 
      and hospital admissions (50.5% versus 13.4% during the first follow-up year) 
      compared to cohort #2. Yearly costs were over three-fold for cohort #1 versus #2, 
      main drivers being hospitalizations in the former and drugs in the latter. 
      Two-year cardiovascular events were recorded significantly more commonly in 
      cohort #4 compared to the other cohorts. Guideline-recommended lipid-lowering 
      therapy was <80% in all but cohort #4. CONCLUSIONS: The present analysis points 
      to three areas of potential improvement in T2DM management: (a) 
      guideline-recommended treatment patterns of T2DM patients; (b) three-fold 
      recurrences and costs in T2DM patients with, compared to those without, prior 
      cardiovascular events; (c) high event rates associated with chronic CAD and PCI, 
      warranting specific studies aimed at improved prevention.
CI  - (c) The Author(s), 2021.
FAU - Maggioni, Aldo Pietro
AU  - Maggioni AP
AUID- ORCID: 0000-0003-2764-6779
AD  - Fondazione Ricerca e Salute (ReS), Rome, Italy ANMCO Research Center, Fondazione 
      per il Tuo cuore - HCF onlus, Via La Marmora 34, Florence, 50121, Italy.
FAU - Dondi, Letizia
AU  - Dondi L
AD  - Fondazione Ricerca e Salute (ReS), Rome, Italy.
FAU - Andreotti, Felicita
AU  - Andreotti F
AD  - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
FAU - Ronconi, Giulia
AU  - Ronconi G
AD  - Fondazione Ricerca e Salute (ReS), Rome, Italy.
FAU - Calabria, Silvia
AU  - Calabria S
AD  - Fondazione Ricerca e Salute (ReS), Rome, Italy.
FAU - Piccinni, Carlo
AU  - Piccinni C
AUID- ORCID: 0000-0002-8648-8961
AD  - Fondazione Ricerca e Salute (ReS), Rome, Italy.
FAU - Pedrini, Antonella
AU  - Pedrini A
AD  - Fondazione Ricerca e Salute (ReS), Rome, Italy.
FAU - Esposito, Imma
AU  - Esposito I
AD  - Fondazione Ricerca e Salute (ReS), Rome, Italy.
FAU - Martini, Nello
AU  - Martini N
AD  - Fondazione Ricerca e Salute (ReS), Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20210622
PL  - United States
TA  - Ther Adv Chronic Dis
JT  - Therapeutic advances in chronic disease
JID - 101532140
PMC - PMC8221674
OTO - NOTNLM
OT  - big data
OT  - coronary artery disease
OT  - diabetes mellitus
OT  - public health practice
COIS- Conflict of interest statement: APM received fees from Astra Zeneca, Bayer, 
      Novartis, Fresenius for participation in study committees, outside the present 
      work. FA reports speaker/consultancy fees from Amgen, Bayer, BMS/Pfizer and 
      Daiichi Sankyo, outside the present work. LD, GR, SC, CP, AP, IE and NM have no 
      conflicts of interest to disclose.
EDAT- 2021/07/06 06:00
MHDA- 2021/07/06 06:01
PMCR- 2021/06/22
CRDT- 2021/07/05 10:05
PHST- 2020/12/07 00:00 [received]
PHST- 2021/06/01 00:00 [accepted]
PHST- 2021/07/05 10:05 [entrez]
PHST- 2021/07/06 06:00 [pubmed]
PHST- 2021/07/06 06:01 [medline]
PHST- 2021/06/22 00:00 [pmc-release]
AID - 10.1177_20406223211026390 [pii]
AID - 10.1177/20406223211026390 [doi]
PST - epublish
SO  - Ther Adv Chronic Dis. 2021 Jun 22;12:20406223211026390. doi: 
      10.1177/20406223211026390. eCollection 2021.